Skip to main content
Clinical Trials/CTRI/2017/08/009262
CTRI/2017/08/009262
Not yet recruiting
未知

A Non-Interventional, Multicenter, Prospective, Observational, Comparative Study to Understand Usage, Safety and Effect of TENeligliptin Vs. GLImepiride as an Add-on to METformin Treatment in Indian Type 2 Diabetes Patients - TENGLIMET

Torrent Pharmaceuticals Ltd0 sites0 target enrollmentTBD

Overview

Phase
未知
Intervention
Not specified
Conditions
Not specified
Sponsor
Torrent Pharmaceuticals Ltd
Status
Not yet recruiting
Last Updated
4 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
4 years ago
Study Type
Observational

Investigators

Eligibility Criteria

Inclusion Criteria

  • 1\.Patient willing to provide informed consent
  • 2\.Female or male patient aged 18 years or above
  • 3\.Adult patients who had inadequately controlled type 2 diabetes mellitus despite using diet plus exercise and metformin:
  • â??HbA1C: 7 to 9%
  • â??FBG: \>\=140 mg/dL
  • 4\.Physician prescribes teneligliptin or glimepiride as an add\-on to metformin therapy
  • 5\.Patients must provide written consent to use personal and/or health data prior to the entry into the study

Exclusion Criteria

  • 1\.Patients with Type 1 diabetes mellitus
  • 2\.Patient on antidiabetic therapy other than glimepiride, teneligliptin and metformin
  • 3\.Contraindications for teneligliptin and glimepiride as per respective approved prescribing information
  • 4\.Any reasons of medical and non\-medical character, which in the opinion of the physician can prevent participant participation in the study
  • 5\.Pregnant and lactating woman and women of child bearing potential not ready to use an effective barrier contraceptive method during the study

Outcomes

Primary Outcomes

Not specified

Similar Trials